Management of advanced renal cell carcinoma / 国际外科学杂志
International Journal of Surgery
; (12): 328-331, 2010.
Article
in Zh
| WPRIM
| ID: wpr-389592
Responsible library:
WPRO
ABSTRACT
Radiotherapy and chemotherapy have little or no effect on advanced renal cell carcinoma, leading to a poor prognosis. Several factors couLd affect the survival rate of RCC. Some RCC patients could partly respond to immunotherapy.The newly emerging targeted therapy has a dramatic tuning point in improving outcomes for RCC. Further understanding of the anti-RCC mechanisms involves in chemokine-mediated angiogenesis and RCC cell proliferation. These new agents include Sorafenib, Sunitinib, Temsirolimus, Bevacizumab, etc. Combination treatment with immunotherapy may lead to improved outcomes in this disease.
Full text:
1
Index:
WPRIM
Type of study:
Prognostic_studies
Language:
Zh
Journal:
International Journal of Surgery
Year:
2010
Type:
Article